Navigation Links
Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
Date:5/23/2013

LAUSANNE, Switzerland and DRESDEN, Germany, May 23, 2013 /PRNewswire/ --

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

Under the research framework's first project, Cenix will apply its leading expertise in combining high throughput screening with high content assays in cultured human cells, to identify predictive biomarkers for Debiopharm preclinical oncology candidates. Multi-parametric microscopy-based readouts established by Cenix using the Definiens XD image analysis platform will be used in a range of human cancer cell models to identify genes and pathways that either enhance or suppress the drug's therapeutic effects. As such, the study represents another important illustration of Debiopharm's ongoing drive to integrate cutting edge technologies and powerful post-genomic strategies towards further refining its personalized medicine approach towards the development of new therapeutics.

"We are very excited to launch this new relationship with Debiopharm, extending their repertoire with what we consider to be some of the most strategically powerful cell-based screening paradigms developed to date," said Dr. Christophe Echeverri , CEO/CSO of Cenix BioScience. "We deeply appreciate and are particularly gratified by this implied trust from yet another world-class and forward-leaning drug development organization, who also happens to be a long-standing expert in R&D outsourcing."

"We look forward to working with Cenix, whose specialist expertise, longstanding leadership and unrivaled track record in this field made them an ideal partner," commented Dr. Hiroaki Tanaka , Director of Personalized Medicine, Debiopharm. "The opportunity to benefit from such depth of knowledge, experience and extensively validated capabilities is considered as the most strategically important resource for preclinical biomarkers discovery."

About Cenix BioScience

With operations in Germany, Belgium and the U.S., Cenix BioScience conducts contract research and develops new reagent technologies focused on a wide array of preclinical cell-based and in vivo applications including RNAi-based gene silencing, miRNA modulation, compound testing, advanced genomics analyses and high content screening to accelerate drug discovery and development. Now in its 14th year, Cenix has built up leading scientific and commercial track records, successfully advancing therapeutic programs for numerous top industry and academic partners in a broad range of disease fields. This success, illustrated by a high rate of repeat business from top clients, is anchored in the consistent application of industrial best practices within fully customized, multi-staged projects designed to offer maximal strategic value and accountability with carefully minimized risk and full data transparency. For more information, please visit the company's web site: http://www.cenix.com

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™, please visit: http://www.debiopharm.com

Cenix and the Cenix BioScience logo are registered trademarks owned by Cenix BioScience GmbH.

Definiens XD and Definiens are registered trademarks owned by Definiens AG.

Debiopharm S.A. Contact
Beatrice Hirt
Communication Coordinator
bhirt@debiopharm.com
Tel: +41-21-321-0111

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf , Ph.D.
Account Executive
Tel: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com

Cenix EU Contact
Dr. Christoph Sachse
Director Cell-based Services
Tel: +49-351-4173-0
info@cenix.com

Cenix USA Contact
Dr. Sirid Kellermann
Director of Marketing
Tel: +1-650-996-9927
kellermann@cenix.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
2. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
3. Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
4. Sangamo BioSciences Reports First Quarter 2013 Financial Results
5. Neurocrine Biosciences Reports First Quarter 2013 Results
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Register by April 30th to get the Discounted Rate for Association of Bioscience Financial Officers (ABFO) 2013 National Conference - San Diego
8. CytoVas And BD Biosciences Ink Alliance To Co-Develop Personalized Diagnostic For Vascular Health
9. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
10. Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
11. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Despite the recent ... slower than other industries to embrace Big Data due ... utilization. On the medical side, organizations have begun looking ... from clinical trials to adherence. --> ... benchmarking firm Best Practices, LLC, Big Data has started ...
(Date:2/5/2016)...  As people age, it is natural to be ... and tests that are linked with certain age milestones ... majority of aging individuals, hearing health is too frequently ... million American adults who report some trouble hearing, there ... health a 2016 healthy aging priority.[1] Cochlear ...
(Date:2/5/2016)... Feb. 5, 2016  Venice,s newest laser clinic, ... first of its kind in the area and ... advanced laser treatment. The physician-owned and operated laser ... Suncoast by storm with its revitalizing skin care ... multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
Breaking Medicine Technology:
(Date:2/5/2016)... Buffalo, NY (PRWEB) , ... February 05, 2016 ... ... regional partners and setting the stage for new clinical and scientific initiatives have ... one year after she was appointed President and CEO of the nation’s oldest ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... of micro-needling services in their Napa Valley office. The technique utilizes the body’s ... Associates, Dr. Canales and Dr. Furnas, are part of only a select few ...
(Date:2/5/2016)... , ... February 05, 2016 , ... After years as ... Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of ... He successfully completed his first three-year term as chief and began a second three-year ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
Breaking Medicine News(10 mins):